Back

ARNI effects in HFrEF. Risk reduction beyond LVEF

29 August 2022 (15:50 - 16:00)
Organised by:
Congress Presentation Part of: Neprilysin inhibition: news and nuggets Treatment ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Andreas Boehmer

St. Josefs- Hospital Wiesbaden, Wiesbaden (Germany)

5 More presentations in this session

Presentation thumbnail
Effects of sacubitril-valsartan on clinical, echocardiographic and polygraphic parameters in patients affected by heart failure with reduced ejection fraction and sleep apnea
Doctor G. Armentaro (Catanzaro, IT)
Abstract Slides Video
Presentation thumbnail
Sacubitril/valsartan compared to ramipril in high risk post myocardial infarction patients stratified according use of mineralocorticoid receptor antagonists: Insight from PARADISE MI trial
Professor M. Schou (Gentofte, DK)
Abstract Slides Video
Presentation thumbnail
Prevalent and incident anaemia in PARADIGM-HF and effect of sacubitril/valsartan
Doctor J. Curtain (Dublin, IE)
Abstract Slides Video
Presentation thumbnail
Effects of angiotensin receptor-neprilysin inhibitors (ARNIs) on the glucose and fat metabolism biomarkers leptin and fructosamin
Doctor B. Ohnewein (Salzburg, AT)
Abstract Slides Video
Presentation thumbnail
Effect of sacubitril/valsartan on endothelial dysfunction and arterial stiffness in patients with chronic heart failure
Doctor V. Cassano (Catanzaro, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Neprilysin inhibition: news and nuggets
Video

The Event

Event poster

ESC Congress 2022

29 August 2022 15:50 CET
You may be interested in
thumbnail
Congress Session
Pulmonary hypertension & acute arrhythmias are cardiac care challenges. How to effectively treat them with drugs
thumbnail
Congress Session
Treatment of HFrEF
thumbnail
Congress Presentation
Autonomic dysregulation as a therapeutic target

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources